Clinical trials: Radiotherapy, Intensity-Modulated
Cancer of the Pharynx, Cancer of the Larynx
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms
- Trial name
- NCT00970502
- Testing
- erlotinib + celecoxib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johnny Kao
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Oral Mucositis
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients…
- Trial name
- NCT03689712
- Testing
- GC4419 90mg
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 455 people
- Sponsor
- Galera Therapeutics, Inc.
Breast Cancer, Radiation Toxicity
Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer
To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control
- Trial name
- NCT03471741
- Testing
- IMRT with concomitant boost, 3D-RT with sequential boost
- Volunteers
- 451 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Postsurgery Recurrent Carcinoma Cervix
Tomotherapy in Postsurgery Recurrent Carcinoma Cervix
Radiotherapy is the most appropriate treatment for postoperative recurrent carcinoma cervix. However it is technically difficult to deliver adequate doses of RT due to presence of small intestines in the radiation area; thus…
- Trial name
- NCT01117402
- Testing
- Radiotherapy
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Tata Memorial Hospital
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Carcinoma, Squamous Cell
Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
The aim of this study is to find the safe dose and best dosing schedule of olaparib to give in combination with cisplatin based chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer.
- Trial name
- ORCA (NCT01491139)
- Testing
- olaparib, cisplatin, Intensity Modulated Radiotherapy
- Sponsor
- University College, London
Breast Cancer
Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation
The aim of this Phase 3 randomised trial is to compare the efficacy and safety of whole breast radiotherapy to accelerated partial breast irradiation using intensity-modulated radiotherapy technique in selected early breast…
- Trial name
- NCT02104895
- Testing
- Accelerated partial breast irradiation (APBI), Whole breast irradiation (WBI)
- Volunteers
- 520 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Soft Tissue Sarcoma
Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)
Intervention prospective monocentric one arm study on the use of neoadjuvant radiotherapy with simultaneous integrated boost (Simultaneous Integrated Boost, SIB) in patients with STS with indication for preoperative radiotherapy.
- Trial name
- SPRINT (NCT05761054)
- Testing
- RT
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Stage III Non-Small Cell Lung Cancer
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.
- Trial name
- NCT00938418
- Testing
- Dose escalated, accelerated, hypofractionated radiotherapy
- Where
- 3 sites in Singapore
- Volunteers
- 43 people
- Sponsor
- National University Hospital, Singapore
Soft Tissue Sarcoma
Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)
To investigate the safety and efficacy of preoperative moderately fractionated IMRT and concurrent Fluzoparib Hydrochloride for primary truncal or extremity soft tissue sarcoma.
- Trial name
- SPARE-03 (NCT05938374)
- Testing
- Fluzoparib, Preoperative moderately fractionated radiotherapay
- Where
- 2 sites in China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophagus Cancer, Unresectable Malignant Neoplasm
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer.
- Trial name
- ARION (NCT03777813)
- Testing
- Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
- Where
- 7 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Prostate Carcinoma, Rectum Carcinoma
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation
Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when…
- Conditions
- Prostate Carcinoma, Rectum Carcinoma, Anal Canal Carcinoma, Endometrium Carcinoma
- Trial name
- MIFADORESOL (NCT04626466)
- Testing
- Biological investigations
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer
Anatomical changes that take place during Intensity modulated radiation therapy (IMRT) treatments for cancers of the head and neck cause significant dosimetric changes.
- Trial name
- NCT02003482
- Testing
- Postop IMRT for head/neck cancer, CT for Radiation Treatment Planning
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Miami
Hepatocellular Carcinoma, Radiotherapy, Sorafenib
Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma
This is a single-arm phase II clinical trial to investigate the efficacy and toxicity of concurrent sorafenib and intensity-modulated radiotherapy (IMRT) for advanced hepatocellular carcinoma with portal vein or hepatic vein…
- Trial name
- SIRAHCC (NCT03535259)
- Testing
- concurrent sorafenib and IMRT, followed sorafenib maintenance
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chemoradiation, Nasopharyngeal Carcinoma
Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb) will receive either cisplatin plus 5-fluorouracil (PF) or docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy with concurrent…
- Trial name
- ESNCCT (NCT01536223)
- Testing
- PF (cisplatin and 5-fluorouracil) group, TPF (docetaxel plus cisplatin and 5-fluorouracil) group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
Study Objective: Primary 1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with…
- Trial name
- NCT01326559
- Testing
- Docetaxel, Cisplatin, 5-FU and Cetuximab
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.